Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has shown strong commercial execution, particularly with the easing of REMS requirements for its product, FILSPARI, which is expected to enhance prescriber adoption. The solid position of sparsentan as a foundational therapy in IgA nephropathy, along with accelerating sales and progress in the Japanese regulatory pathway, reflects substantial growth potential. The favorable stock market reaction following the cancellation of the Advisory Committee meeting further underscores the positive sentiment surrounding the company's recent developments.

Bears say

The negative outlook on Travere Therapeutics's stock is primarily driven by potential challenges in securing future funding and the risk of failed or inconclusive clinical trials for its pipeline candidate, sparsentan, which targets rare kidney disorders. Increased scrutiny stemming from recent FDA actions, including leadership changes and shifting review practices, has heightened uncertainty and prompted investor trepidation within the biotech sector. Overall sentiment has been mixed regarding regulatory decisions, posing additional risks to the company's development pathway and investor confidence.

Travere Therapeutics (TVTX) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 12 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.